Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60Leukemia 32Gastrointestinal Stromal Tumors 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Chronic-Phase 21Blast Crisis 9Philadelphia Chromosome 8Neoplasm Metastasis 8Melanoma 8Lung Neoplasms 8Brain Neoplasms 7Sarcoma 6Prostatic Neoplasms 6Neoplasms 6Recurrence 5Ovarian Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Small Cell Lung Carcinoma 4Primary Myelofibrosis 4Polycythemia Vera 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Acute 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myeloid 4Dermatofibrosarcoma 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms 4Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3

Interventions

Radiotherapy 3Temozolomide 2Tamoxifen 2Magnetic Resonance Spectroscopy 2sargramostim 1aldesleukin 1Topotecan 1Surgical Procedures, Operative 1Reverse Transcriptase Polymerase Chain Reaction 1Muromonab-CD3 1Modafinil 1Mental Status and Dementia Tests 1Lapatinib 1Immunologic Techniques 1Immunoenzyme Techniques 1Imatinib Mesylate 1Ginkgo biloba extract 1Gefitinib 1FANG vaccine 1Drug Therapy 1Doxorubicin 1Donepezil 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Glioma, Subependymal × Imatinib Mesylate × Clear all
NCT00039364 2012-07-24

Imatinib Mesylate in Treating Patients With Gliomas

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
112 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡